ARIBIOLAB
KKRX:2617803,635.00
KRW
-245.00
(-6.31%)
ISIN
KR7261780001
Return %
Stock
S&P 500
1Y
39.54
13.14
3Y
-22.82
80.78
5Y
-72.04
67.74
Capital Structure
KRW
•
in mil. unless spec.Working Capital
KRW
•
in mil. unless spec.Growth Rates
KRW
•
in mil. unless spec.Quarterly Revenue
KRW
•
in mil. unless spec.Quarterly Earnings Per Share
KRW
•
in mil. unless spec.Quarterly Dividends Per Share
KRW
•
in mil. unless spec.Company Description
- CEO
- Seong-Il Han
- Full Time Employees
- 49
- Sector
- Health technology
- Industry
- Biotechnology
- Address
- Seongnam-si South Korea
- IPO Date
- Oct 22, 2021
- Website
- chavaccine.com
- Similar Companies
- Business
- ARIBIOLAB Co., Ltd. (KRX: 261780) is a South Korea-based biopharmaceutical and healthcare company primarily engaged in the discovery, clinical development, and commercialization of small-molecule therapeutics for central nervous system disorders, as well as the manufacturing and distribution of health functional foods, cosmeceuticals, and bio-wellness products. Founded in 2010 and headquartered in Seongnam, Gyeonggi-do, South Korea, the company operates across pharmaceutical biotechnology, functional nutrition, and consumer healthcare business segments, targeting domestic and global medical, institutional, and retail markets. The company offers a diversified portfolio of therapeutic drug candidates, consumer healthcare products, and bio-manufacturing solutions; its biopharmaceutical pipeline is led by AR1001, an orally administered multi-mechanism phosphodiesterase-5 (PDE5) inhibitor designed to provide neuroprotective effects, enhance synaptic plasticity, and reduce neuronal apoptosis in early-stage Alzheimer's disease; AR1002, an investigative therapeutic candidate targeting vascular dementia and ischemic brain injury; AR1003, a combination drug regimen developed for advanced dementia; AR1004, a development candidate focused on metabolic and infectious indications; and AR1005, a small-molecule agent under exploration for amyotrophic lateral sclerosis (ALS) and related neurodegenerative conditions; its consumer healthcare and wellness product offerings comprise health functional foods and dietary supplements, including immune-support formulations, vitamin and mineral complexes, and targeted nutritional supplements; dermatological cosmeceuticals and functional skincare lines featuring anti-aging creams, rejuvenating serums, and cleansers based on proprietary bio-ingredients; functional mineral water technologies and enriched hydration products; and contract development, formulation, and original equipment manufacturing (OEM) and original design manufacturing (ODM) services for third-party wellness and skincare enterprises. In recent developments, ARIBIOLAB has advanced the global clinical footprint of its lead drug candidate AR1001 by progressing its pivotal multi-region Phase 3 clinical trial (POLARIS-AD) across investigative sites in the United States, Europe (including the United Kingdom, France, Germany, Spain, and Italy), South Korea, and Greater China following investigational new drug (IND) clearances from the U.S. FDA, the European Medicines Agency (EMA), the UK MHRA, and China's NMPA. In addition, the company established strategic commercialization alliances, including an exclusive licensing and distribution agreement with Samjin Pharm Co., Ltd. for the South Korean market, alongside regional licensing partnerships in Asian territories to prepare for market distribution upon regulatory approval. Furthermore, the company completed a strategic corporate restructuring and equity alignment in collaboration with Solux Co., Ltd. to consolidate resources, secure long-term clinical financing, and streamline its corporate governance structure for cross-border expansion and capital market milestones. ARIBIOLAB continues to scale its international clinical research operations, expand its intellectual property estate across neurodegenerative disease platforms, and broaden its commercial distribution channels across Asia, Europe, and North America.